Results 311 to 320 of about 198,722 (342)

Beyond BRAF in Melanoma

2010
Recent progress in the analysis of genetic alterations in melanoma has identified recurrent mutations that result in the activation of critical signaling pathways promoting growth and survival of tumors cells. Alterations in the RAS-RAF-MAP kinase and PI3-kinase signaling pathways are commonly altered in melanoma. Mutations in BRAF, NRAS, KIT, and GNAQ
Adil, Daud, Boris C, Bastian
openaire   +2 more sources

?????????????????????? ???????????????? ???????????????????????? ?????? ???????????????? ???????? ?? ???????????????? BRAF V600E

2018
?? 40???60% ?????????????? ???????????????? ???????? ???????????????? ?????????????? ???????????????? BRAF, ???????????????????? ?????????????? ???????????????? ???????????????????????????? ?????????????????? ???????????????????????????????? ???????????? BRAF ??, ????????????????????????????, ?????????????????????? ?????????????? ???? ???????? MAPK/ERK.
Chapman, P.B., Hauschild, A., Robert, C.
openaire   +1 more source

BRAF

2020
Daniela Furlan, Nora Sahnane
openaire   +1 more source

Inhibition of BRAF and MEK in BRAF-mutant melanoma

The Lancet, 2015
Keiran S M, Smalley, Vernon K, Sondak
openaire   +2 more sources

braf check

2021
openaire   +1 more source

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

The Lancet Oncology, 2010
W. De Roock, B. Claes, David Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, K. Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig, F. Penault-Llorca, P. Rougier, B. Vincenzi, D. Santini, G. Tonini, F. Cappuzzo, M. Frattini, F. Molinari, P. Saletti, S. De Dosso, M. Martini, A. Bardelli, S. Siena, A. Sartore-Bianchi, J. Tabernero, T. Macarulla, F. Di Fiore, A. Gangloff, F. Ciardiello, P. Pfeiffer, C. Qvortrup, T. P. Hansen, E. Van Cutsem, H. Piessevaux, D. Lambrechts, M. Delorenzi, S. Tejpar   +36 more
semanticscholar   +1 more source

BRAF-V600E

2013
Stephan Mose, Stephan Mose, Brandon J. Fisher, Iris Rusu, Charlie Ma, Lu Wang, Larry C. Daugherty, Brandon J. Fisher, Stephan Mose, Tod W. Speer, Tod W. Speer, Anthony E. Dragun, Rene Rubin, Claudia Rübe, James H. Brashears, Stephan Mose, James H. Brashears, Christian Weiss, Claus Roedel, Christian Weiss, Claus Roedel, Edward J. Gracely, Rene Rubin, Lindsay G. Jensen, Brent S. Rose, Loren K. Mell, Arno J. Mundt, Iris Rusu, Anthony E. Dragun, Anthony E. Dragun, Albert S. DeNittis, Christin A. Knowlton, Michelle Kolton Mackay, Yan Yu, Laura Doyle, Cheng B. Saw, Yan Yu, Laura Doyle, Ning J. Yue, Rene Rubin, Nisha R. Patel, Michael L. Wong, Brian F. Hasson, Daniel Yeung, Jatinder Palta, Christin A. Knowlton, Michelle Kolton Mackay, James H. Brashears, Anthony E. Dragun, Anthony E. Dragun, David E. Wazer, Anthony E. Dragun, Anthony E. Dragun, Stephan Mose, Susan M. Varnum, Marianne B. Sowa, William F. Morgan   +56 more
openaire   +1 more source

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Nature, 2012
A. Prahallad, Chong Sun, Sidong Huang, F. Nicolantonio, R. Salazar, D. Zecchin, R. Beijersbergen, A. Bardelli, R. Bernards   +8 more
semanticscholar   +1 more source

Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma

Nature Reviews Clinical Oncology, 2013
Jane L Messina, Vernon K Sondak, Keiran S M Smalley   +2 more
exaly  

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Nature Medicine, 2019
P. Ascierto, P. Ferrucci, R. Fisher, M. Del Vecchio, V. Atkinson, H. Schmidt, J. Schachter, P. Queirolo, G. Long, A. D. Di Giacomo, I. Svane, M. Lotem, G. Bar-Sela, F. Couture, B. Mookerjee, R. Ghori, N. Ibrahim, B. H. Moreno, A. Ribas   +18 more
semanticscholar   +1 more source